^
    Back
    Association details:
    Biomarker:PD-L1 negative
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

    Excerpt:
    ...Objective response rate (ORR) in PD-L1 positive (PD-L1 ≥1%) and PD-L1 negative (PD-L1 nd tolerability of Nivolumab and Ipilimumab combined with chemotherapy.`...
    Trial ID:
    CheckMate 568
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression

    Published date:
    10/16/2023
    Excerpt:
    In the dual group, patients with PD-L1 TPS 0-20% had significantly longer PFS (10.5 months (5.0-NA) vs. 4.1 months (0.23-NA), p=0.017) and OS (NA months (18.6-NA) vs. 9.0 months (0.23-NA), p=0.0014) than those with PD-L1 TPS 21-49%....The results suggest that nivolumab and ipilimumab-based therapy may be a better treatment option, especially for patients with negative and lower PD-L1 TPS (<20%).